BIOKIER, INC.
Orally administered therapeutic (BKR-017) using butyrate delivery to restore gut hormone secretion in the colon
- Sector
- Biotech
- Headquarters
- CHAPEL HILL, NC
- Founded
- 2008
- Latest Form D
- $150K, Aug 2014
- Total capital
- $6.1M
- Federal grants
- $5.2M
- 8 awards · 2015–2024
- Rank in peer group#153 of 514
- Private capital raised
- $985K
- 5 Form D · last Aug 2014
- 147 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 20 pending · first 2014
- Rank in peer group#109 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Clinical development of a colon-targeted butyrate tablet to evaluate effects on cholesterol and trimethyl amine oxide in subjects at risk for cardiovascular disease$436K
- Federal grantHealth and Human S · Phase II · Development of an oral therapeutic to mimic the anti-diabetic effects of gastric bypass surgery$1.0M
- Federal grantHealth and Human S · Phase II · Development of an oral therapeutic to mimic the anti-diabetic effects of gastric bypass surgery$1.0M
- Federal grantHealth and Human S · Phase II · Development of an oral therapeutic to mimic the anti-diabetic effects of gastric bypass surgery$1.0M
- Federal grantHealth and Human S · Phase II · Development of an oral therapeutic to mimic the anti-diabetic effects of gastric bypass surgery$120K
- Federal grantHealth and Human S · Phase II · Development of an oral therapeutic to mimic the anti-diabetic effects of gastric bypass surgery$250K
- Federal grantHealth and Human S · Phase II · Development of an oral therapeutic to mimic the anti-diabetic effects of gastric bypass surgery$1.1M
- Private capital raisedForm D · SEC · 5th filing$150K
- Private capital raisedForm D · SEC · 4th filing$645K
- Private capital raisedForm D · SEC · 3rd filing$40K
- Private capital raisedForm D · SEC · 2nd filing$50K
- Private capital raisedForm D · SEC · 1st filing$100K
Show 1 earlier federal award
- Federal grantHealth and Human S · Phase II · Development of an oral therapeutic to mimic the anti-diabetic effects of gastric bypass surgery$224K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#153 · top 30%
- Granted patents#109 · top 21%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Jerzy R SzewczykResearcherExecutive Officer, DirectorLinked by $5.2M in grants as PI
- James R FarrellyDirectorNamed in SEC Form D filings
- Roger NolanExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 23- PendingComposition And Method For Treatment Of DiabetesUSPTOApplication 19375403
- PendingMethod And Composition For Lowering Total Systemic Cholestrol, Ldl Cholesterol, And Non-hdl CholesterolUSPTOApplication 18430750
- PendingComposition And Method For Treatment Of DiabetesUSPTOApplication 17527401
Show all 23 patent records
- Composition And Method For Treatment Of DiabetesMay 14, 2026 · Application 19375403Pending
- Method And Composition For Lowering Total Systemic Cholestrol, Ldl Cholesterol, And Non-hdl CholesterolMay 23, 2024 · Application 18430750Pending
- Composition And Method For Treatment Of DiabetesJan 4, 2024 · Application 17527401Pending
- Composition And Method For Treatment Of DiabetesJun 22, 2023 · Application 17554076Pending
- Composition And Method For Treatment Of DiabetesMay 18, 2023 · Application 17557962Pending
- Composition And Method For Treatment Of DiabetesMay 4, 2023 · Application 17518952Pending
- Composition And Method For Treatment Of DiabetesDec 8, 2022 · Application 17890655Pending
- Composition And Method For Treatment Of DiabetesMar 10, 2022 · Application 17527263Pending
- Composition And Method For Treatment Of DiabetesFeb 24, 2022 · Application 17518939Pending
- Stabilized Coated Butyrate For Colon ReleaseSep 2, 2021 · Application 16805080Pending
- Composition And Method For Treatment Of DiabetesAug 29, 2019 · Application 16405424Pending
- Composition And Method For Treatment Of NashApr 19, 2016 · US 9,314,444Granted
- Composition And Method For Treatment Of DiabetesAug 13, 2015 · Application 14695439Pending
- Composition And Method For Treatment Of DiabetesApr 14, 2015 · US 9,006,288Granted
- Composition And Method For Treatment Of DiabetesMar 12, 2015 · Application 14020294Pending
- Composition And Method For Treatment Of DiabetesMar 25, 2014 · US 8,680,085Granted
- Composition And Method For Treatment Of DiabetesApplication PCTUS2010020629Pending
- Treatment With Colon Targeted Butyrate For Reduction Of Trimethylamine N-oxideApplication PCTUS2024052475Pending
- Treatment Of Weight Regain After Discontinued Use Of Anorectic DrugsApplication PCTUS2024042669Pending
- Method And Composition For Lowering Total Systemic Cholesterol, Ldl Cholesterol, And Non-hdl CholesterolApplication PCTUS2021023841Pending
- Stabilized Coated Butyrate For Colon ReleaseApplication PCTUS2021019911Pending
- Composition And Method For Treatment Of DiabetesApplication PCTUS2012036077Pending
- Composition And Method For Treatment Of DiabetesApplication PCTUS2010049843Pending
Related companies, and why
- Adolore Biotherapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- NERX BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- ThinkBio.Ai, IncSimilar federal contract value in Biotech · null in contracts
- Breakaway Labs, Inc.Similar federal contract value in Biotech · null in contracts
- Jupiter Biomedical Research, Inc.Similar federal contract value in Biotech · null in contracts
- Atacama Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .